Alerta

GLUCOSE LEVEL DEVIATION DETECTION

Resumen de: US20260191435A1

0000 Glucose level measurements of a user are obtained over time, such as from a wearable glucose monitoring device being worn by the user. These glucose level measurements can be produced substantially continuously, such that the device may be configured to produce the glucose level measurements at regular or irregular intervals of time, responsive to establishing a communicative coupling with a different device, and so forth. These glucose level measurements are analyzed to detect deviations from past glucose measurements, such as glucose measurements received earlier in the day or glucose measurements received at corresponding times of one or more preceding days. Indications of detected deviations are provided to the user or communicated elsewhere, such as to a healthcare professional.

HCG TUNABLE VCSEL WITH OPTICAL CONFINEMENT VIA STEP INDEX AND REGROWTH

Resumen de: US20260196807A1

A glucose detection or monitoring system that includes a VCSEL laser with one or more active regions having quantum wells and barrier. The active regions are surrounded by one or more p-n junctions. The one or more active regions can include a selected shape structure, and one or more tunnel junctions (TJ). One or more apertures are provided with the selected shape structure, one or more buried tunnel junctions (BTJ) or oxide confine apertured, additional TJ's, planar structures and or additional BTJ's created during a regrowth process that is independent of a first growth process with a VCSEL output determined in response to a monitoring application of the VCSEL, the VCSEL having an HCG grating and a bottom DBR. A housing of a wearable device interior houses the VCSEL laser.

RESPIRATORY THERAPY CONFIGURATION BASED ON GLUCOSE MONITORING AND METABOLIC HEALTH

Resumen de: WO2026148099A1

Techniques for improved respiratory therapy are provided. Glucose data of a user collected during a sleep session is accessed. Based at least in part on the glucose data, a plurality of transitions between sleep stages experienced by the user during the sleep session is determined. A sleep quality measure for the sleep session is generated based at least in part on the plurality of transitions. An apnea risk score for the user is generated based at least in part on the sleep quality measure, and one or more medical interventions for the user are provided based on the apnea risk score.

SYSTEM AND METHOD FOR TITRATING BASAL INSULIN DOSES

Resumen de: US20260192048A1

0000 A continuous glucose monitor (CGM)-driven basal insulin titration system and method for patients with Type 2 Diabetes can be adapted to the needs and concerns of subjects just starting on basal insulin therapy. The method uses as inputs historical CGM data, basal insulin dose information, reports of hypoglycemia, and past recommendations and generates an adjusted insulin dose along with a report advising whether to continue the titration process, or to stop. The method can generate a new recommendation on a regular basis (e.g., each day) until it determines an adequate, consistent dose size.

MEDICAMENT DELIVERY SYSTEM USING LACTATE DATA

Resumen de: WO2026147654A1

A method of delivering a medicament to a subject for the treatment of diabetes includes: receiving glucose data and lactate data for the subject; adjusting medicament therapy to be delivered to the subject based at least in part on the glucose data and the lactate data; and delivering the adjusted medicament therapy to the subject.

HEALTH EDUCATION-INTEGRATED LAUGHTER YOGA EXERCISE INTERVENTION TRAINING METHOD FOR DIABETIC FOOT PATIENTS

Resumen de: LU604632B1

The present invention provides a health education-integrated laughter yoga exercise intervention training method for diabetic foot patients, including: acquiring, in real time, multimodal physiological data of the patient including foot physiological parameters, systemic physiological indicators, and laughter audio signals; determining the patient’s current physiological context in real time based on the data, and dynamically generating a comprehensive intervention strategy; the strategy includes laughter yoga exercise instructions, context-embedded health education content, distributed proprioceptive guidance instructions for real-time posture adjustment guidance, and acoustic resonance induction instructions for emotional regulation; executing the strategy, and performing adaptive adjustment on the decision-making model for generating the strategy according to changes in physiological data after intervention. By constructing a closed-loop system of sensing, decision-making, execution, and feedback, the present invention is capable of providing patients with personalized, safe and dynamically adaptive rehabilitation training programs, achieving the coordinated rehabilitation of physical and psychological states.

SYSTEMS, DEVICES, AND METHODS FOR MEAL INFORMATION COLLECTION, MEAL ASSESSMENT, AND ANALYTE DATA CORRELATION

Resumen de: US20260191433A1

Systems, devices, and methods for detecting, measuring and classifying meals for an individual based on analyte measurements. These results and related information can be presented to the individual to show the individual which meals are causing the most severe analyte response. These results can be organized and categorized based on preselected criteria or previous meals and results so as to organize and present the results in a format with reference to glucose as the monitored analyte. Various embodiments disclosed herein relate to methods, systems, and software applications intended to engage an individual by providing direct and timely feedback regarding the individual's meal-related glycemic response.

A NEW SITE FOR TRANSPLANTATION

Resumen de: US20260191912A1

Methods for transplanting cells or tissues, in particular islets, into a sub-rectus sheath site. Methods for treating diabetes by transplanting islets, particularly hPSC-islets, into a sub-rectus sheath position. The sub-rectus sheath position is a new site for transplantation.

SYSTEM AND METHOD FOR DECISION SUPPORT USING LIFESTYLE FACTORS

Resumen de: US20260192043A1

0000 Systems and methods are provided relating to open loop decision-making for management of diabetes. People with diabetes face many problems in controlling their glucose because of the complex interactions between food, insulin, exercise, stress, activity, and other physiological and environmental conditions. Established principles of management of glucose sometimes are not adequate because there is a significant amount of variability in how different conditions impact different individuals and what actions might be effective for them. Accordingly, systems and methods according to present principles minimize the impact of the vagaries of diabetes on individuals, i.e., by looking for patterns and tendencies of an individual and customizing the management to that individual. Consequently, the same reduces the uncertainty that diabetes typically is associated with and improves quality of life.

Multi-State Engagement With Continuous Glucose Monitoring Systems

Resumen de: US20260191434A1

Multi-state engagement with continuous glucose monitoring (CGM) systems is described. Given the number of people that wear CGM systems and because CGM systems produce measurements continuously, a platform that provides a CGM system may have an enormous amount of data. This amount of data is practically, if not actually, impossible for humans to process. In implementations, a CGM platform includes a data analytics platform that obtains packages of glucose measurements provided by a CGM system and also obtains additional data associated with a user. The data analytics platform generates state information for the user by processing these CGM packages and the additional data, at least in part, by using one or more models. Based on this state information, the data analytics platform controls communication with the user, which may include generating intervention strategies to prevent users from transitioning to a negative state such as discontinuing use of the CGM system.

MITIGATION OF COMPRESSION EVENT FAILURE FOR CONTINUOUS GLUCOSE MONITORS

Resumen de: AU2024395288A1

Certain aspects of the present disclosure relate to methods and systems for distinguishing between temporary compression of a sensor of a continuous analyte monitoring system and failure of the sensor, such as due to detachment of the sensor. In certain aspects, an apparatus includes an analyte sensor, a temperature sensor, a memory, and a processor communicatively coupled to the memory. The processor is configured to evaluate samples of an output of the analyte sensor and samples of an output of the temperature sensor with respect to a threshold condition. If the threshold condition is met, the processor is configured to generate a signal indicating failure of the analyte sensor.

RESPIRATORY THERAPY CONFIGURATION BASED ON GLUCOSE MONITORING AND METABOLIC HEALTH

Resumen de: WO2026148093A1

Techniques for improved respiratory therapy are provided. Glucose data of a user, collected while the user was awake, is accessed, where the user is a participant in a respiratory therapy. A metabolic health (MH) state of the user is determined based at least in part on the glucose data. A respiratory therapy configuration for a subsequent usage session of the user is generated based on evaluating the MH state using one or more MH models. A respiratory therapy flow generator of the user is instructed to implement the respiratory therapy configuration during a usage session.

SENSOR FOR DETECTING GLUCOSE AND LACTATE AND METHODS FOR DETERMINING AEROBIC AND ANAEROBIC THRESHOLDS

Resumen de: US2025169728A1

The present disclosure describes lactate-responsive sensors, sensing systems incorporating a lactate-responsive sensor, and methods of use thereof that would be beneficial for continuously monitoring lactate levels and determining lactate thresholds (both aerobic and anaerobic thresholds). The present disclosure also relates to an analyte sensor for continuously detecting glucose and lactate levels.

Growth factor substituents

Resumen de: GB2644972A

Growth-enhancing peptides and fusion polypeptide are provided. The peptides and fusion polypeptides may be used in cell culture, in particular in the production of cultured meat, as replacement or addition to insulin. There is further provided a cell culture medium comprising at least one of the peptides or fusion polypeptides, and a method for growing cells comprising adding at least one of the peptides or polypeptides to the cell culture medium.

BIOELECTRODE, BIOELECTRODE PRODUCTION METHOD, ELECTROCHEMICAL DEVICE, BLOOD SUGAR LEVEL MEASUREMENT DEVICE, AND CONCENTRATION MEASUREMENT METHOD

Resumen de: EP4773258A1

A bioelectrode includes: a complex compound including a metal and a ligand; a mediator having an anionic functional group; and a conductive material.

COMPOSITION FOR BASAL MEDIUM FOR ANIMAL CELL CULTURE

Resumen de: EP4772611A1

The present invention relates to a basal medium composition for animal cells. The basal medium composition for animal cells according to the present invention contains a yeast extract, amino acids, an inorganic salt, and a sugar, wherein the amino acids in the composition include cystine and/or cysteine, and glutamine.

SYSTEMS AND METHODS FOR FOOD ANALYSIS, PERSONALIZED RECOMMENDATIONS, AND HEALTH MANAGEMENT

Resumen de: US20260182870A1

0000 Techniques disclosed herein relate to food analysis and glucose level management. In some examples, the techniques involve determining a consumption of a food item by a user, receiving data indicative of a glucose level of the user, determining an effect of the food item on the glucose level of the user based on a change of the glucose level of the user, and storing the effect of the food item on the glucose level of the user that includes data associated with one or more effects of the food item on the glucose level of the user.

EXPANSION OF LYMPHOCYTES

Resumen de: US20260183397A1

0000 The present invention relates to a method for expansion of a population of lymphocytes in a controlled single culture vessel, the method comprising a step of (a) culturing a tissue or blood sample from a subject, which sample is known or suspected to contain lymphocytes; or (b) culturing lymphocytes, which lymphocytes are isolated from a tissue or blood sample from a subject; wherein the lymphocytes are expanded in a culture medium in which at least one of the following parameters is monitored and adjusted to a predefined value or range: pH, dissolved oxygen (DO) concentration, glucose concentration, lactate concentration and/or temperature; and wherein the method comprises a step of adjusting the culture volume to the expansion rate of the lymphocytes. Furthermore, the invention relates to a population of lymphocytes comprising at least 90% CD3+ T cells and less than 5% B cells, wherein at least 70% of said T cell portion are viable, optionally, and less than 10% are triple positive for CD45RA, CD57 and KLRG1.

METHODS AND COMPOSITIONS FOR DIABETES TREATMENT AND BETA-CELL REGENERATION

Resumen de: US20260184796A1

0000 Aspects of the present disclosure are directed to methods and compositions for facilitating β-cell regeneration by inhibition of the HIF1α-PFKFB3 pathway. Certain aspects describe methods for treatment and prevention of prediabetes and diabetes, including type 2 diabetes. Also disclosed are methods and compositions for enhancing β-cell regeneration.

BLOOD GLUCOSE DISEASE MANAGEMENT SYSTEM

Resumen de: US20260182931A1

0000 The disease management system can determine a measurement of one or more physiological parameters and can determine a disease event based on the one or more measurements. Furthermore, the disease management system can determine a pose of an individual using a pose sensor. Based on an identification of a disease event and a determination that the pose of the individual corresponds to a first pose, the disease management system can cause at least one of an audible, visual, or vibratory alarm. Based on an identification of a disease event and a determination that the pose of the individual does not correspond to the first pose, the disease management system can cause administration of a medication to the individual.

PERFORMANCE REPORTS ASSOCIATED WITH CONTINUOUS SENSOR DATA FROM MULTIPLE ANALYSIS TIME PERIODS

Resumen de: US20260188503A1

A method of providing performance reports to persons associated with the monitoring of an analyte level, such as blood glucose concentrations in a host, is provided. The performance reports can indicate a measure of an analyte variability of the host over a first analysis time period compared to a measure of analyte variability of the host over one or more other analysis time periods. The analyte level of the host can be received in each of a plurality of sensor readings from a continuous analyte sensor, such as multiple sensor readings per hour, so that the analyte variability that is used in determining the performance report of the host can be based on not just a few metered readings taken by the host, but a plurality of intermittent readings that are taken by a continuous analyte sensor, for example. Various types of performance reports can be generated, such as reports that comprise charts, graphs, tables, and/or other visual indicia of a host's performance during one analysis period versus another analysis period.

VIRTUALLY MONITORING GLUCOSE LEVELS IN A PATIENT USING MACHINE LEARNING AND DIGITAL TWIN TECHNOLOGY

Resumen de: US20260182869A1

0000 A patient health management platform implements a machine-learned metabolic model to generate a prediction of a patient's glucose level. The platform implements a short-term prediction model to generate a daily prediction of the patient's glucose level based on nutrition data reported by the patient and sensor data and lab test data collected for the patient. The platform implements a long-term prediction model generate a prediction of the patient's glucose level during an extended time period based on sensor data and lab test data collected for the patient. Using the short-term prediction model, the long-term prediction model, or both, the patient health management platform generates predictions of the patient's glucose level and updates a digital twin of the patient's metabolic profile.

METHODS, DEVICES, AND SYSTEMS FOR ADJUSTING LABORATORY HBA1C VALUES

Resumen de: US20260188443A1

0000 A method of providing personalized treatment for a diabetes patient including a remote device which is configured to receive a first data indicative of an analyte level of a subject during a first time period, retrieve a first glycated hemoglobin level for the subject associated with the first time period, calculate a first personal apparent glycation ratio for the first time period using the received first data and the retrieved first glycated hemoglobin level, compare the calculated first personal apparent glycation ratio to a representative apparent glycation ratio, generate a recommendation based on the comparison, and display a graphical interface comprising the calculated first personal apparent glycation ratio, the representative apparent glycation ratio, and the comparison.

ARTIFICIAL PANCREAS INTEGRATED CGM ARCHITECTURES AND DESIGNS

Resumen de: US20260183483A1

0000 A system for managing a patient's glucose level includes a glucose sensor to generate and store data signals for measurements of the patient's glucose level made by the glucose sensor; an insulin pump; and sensor electronics operatively coupled to the glucose sensor, the sensor electronics comprising a memory storing one or more predetermined characteristics associated with the sensor electronics; and a computing device in electronic communication with the sensor electronics. The computing device comprises a processor configured to operate the sensor electronics to (i) receive the generated data signals, (ii) obtain the one or more predetermined sensor characteristics from the memory and (iii) execute a closed-loop algorithm to provide insulin delivery instructions to an insulin pump by at least using the data signals and predetermined characteristics.

COMPRESSION EVENT DETECTION FOR CONTINUOUS GLUCOSE MONITORS

Nº publicación: AU2024389410A1 02/07/2026

Solicitante:

DEXCOM INC
DEXCOM, INC

Resumen de: AU2024389410A1

A continuous analyte monitoring system includes first and second analyte sensors configured to sense analytes such as lactate and glucose in the tissue of a user. A controller Is coupled to the analyte sensors and configured evaluate first samples of outputs of the first analyte sensor and second samples of outputs of the second analyte sensor with respect to one another to determine whether the first samples and the second samples indicate compression of the tissue. If the first samples and the second samples indicate compression of the tissue, compensate for the compression of the tissue with respect to the first samples. The controller may evaluate the machine learning models using a machine learning model or a filter.